Intelligence Feed

Articles, research, videos and community discussion.

mike800

I think people overstate what an in-vitro receptor potency number tells us about a peptide. A compound looking impressive in a cell assay does not automatically mean stronger effects in humans; absorption, half-life, tissue distribution, receptor desensitization, and active metabolites can change the whole picture. Even animal results can be misleading when the receptor pharmacology differs between species. Why do so many discussions treat an EC50 or IC50 like it is a clinical ranking? Those numbers are useful, but without the assay conditions and exposure data they are basically being used as marketing shorthand.

387 views comments
Comments 18
eastcoast2

Compared with regular small-molecule meds, peptides seem almost impossible to take by mouth, yet oral semaglutide exists. Is the main problem stomach acid and enzymes destroying the peptide, or that intact peptide can't cross the gut wall? I keep seeing people say “peptides don’t survive digestion” like that explains everything, but it sounds oversimplified. Is oral semaglutide mainly an exception because of its absorption enhancer, the specific molecule, or both?

366 views comments
Comments 25
pete806

The assumption that peptide quality is mainly a purity problem is getting outdated. As GLP-1 demand scales, the bottleneck is increasingly process control: aggregation, stereochemical impurities, residual solvents, and lot-to-lot consistency. A 99% result from one analytical method says little about whether a manufacturer can reproduce the same impurity profile at commercial scale. Scale-up is where the real science shows up.

413 views comments
Comments 25